Market Newsdesk

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure

neffy^®

(epinephrine nasal spray) 2 mg for undesignated use meets applicable state law requirements

Interested schools can visit


neffy.com

/community-programs

to apply

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today the launch of the neffyinSchools program. neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons (four single use doses) of neffy^® (epinephrine nasal spray) 2 mg for use in emergency situations at no cost to the school via the School Health Corp. SHConnect platform. neffy 2 mg is approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). Participating schools will be eligible to receive replacement doses when the product is used or expires.

“School nurses play a pivotal role in the health and wellbeing of students. Unexpected allergic reactions can happen at any time – including during the school day – so it is crucial to have epinephrine readily available to administer by nurses and other trained school officials. The neffyinSchools program will help schools to obtain epinephrine free of cost. This positions schools to be ready to provide emergency treatment for severe allergic reactions,” said Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America.

Life-threatening, Type 1 allergic reactions can happen quickly and be caused by foods, insects, medication, exercise, or other unknown causes. It is estimated that one-quarter of anaphylactic reactions in schools are among students with previously undiagnosed allergies.¹ Studies also show that food allergy affects approximately 1 in 20 school-aged children.²

“We are deeply committed to ensuring neffy is freely available to all eligible K-12 schools, providing life-saving epinephrine for emergency situations without fear or hesitation,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis can progress rapidly and occur at any time, many states must update their legislation to include nasal delivery in local epinephrine stocking and indemnification laws, for undesignated use, before it can be provided to schools.”

ARS Pharma will host a webinar for school nurses and administrators about neffy and the neffyinSchools program on January 22, 2025. Participants are encouraged to register here.

For more information, including details about patient advocacy groups and resources for schools, visit www.neffy.com/community-programs. For specific inquiries, please email [email protected]. Ongoing updates will be provided on ARS LinkedIn and X pages.

About

neffy

inSchools

ARS Pharma is committed to working with our communities to provide essential epinephrine in schools. Eligible public and private K-12 schools in the U.S. (excluding territories) will be able to receive two cartons (four single use doses) of neffy 2 mg for adults and children who weigh ≥30 kg (66 lbs.), in emergency situations. The neffyinSchools program is only for undesignated use, and children with prescriptions for epinephrine from their healthcare provider must continue to supply medication to their school in accordance with school guidelines. Schools must review applicable state legislation to ensure neffy meets the requirements of local epinephrine stocking and administration laws for undesignated use. The supplemental NDA for neffy 1 mg dose was granted priority review by the FDA and has a PDUFA date set for March 6, 2025. If approved, neffy 1 mg will be available to schools for students who weigh between 33 and 66 lbs.

About

neffy



^®




neffy
is an intranasal epinephrine product for patients with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)

INDICATION
neffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.

IMPORTANT SAFETY INFORMATION
It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

neffy
is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy
may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Adverse reactions to neffy may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information on neffy, please see Full Prescribing Information at www.neffy.com.

About Type I Allergic Reactions Including Anaphylaxis

Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® 2 mg (trade name EURneffy^® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the expected timing and launch of neffyinSchools; the needle-free profile of neffy and making neffy available at no cost to eligible public and private K-12 schools increasing the likelihood that such schools will both carry and administer epinephrine to students experiencing an allergic reaction; the expectation that neffy will save lives; the potential for neffy to qualify under local and state stocking and indemnification laws for undesignated use; the expected timing for obtaining regulatory approval for neffy 1 mg and the availability thereof; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expects,” “if,” “may,” “potential,” “on track to,” “plans,” “will,” “would,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; ARS Pharmaceuticals may not receive the anticipated benefits from the neffyinSchools program; public and private schools may not participate in the neffyinSchools program to the degree or on the timelines expected by ARS Pharmaceuticals; the scope, progress and expansion of developing and commercializing neffy; the potential for payors to delay, limit or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; and ARS Pharmaceuticals’ ability to protect its intellectual property position; the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharmaceuticals’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (“SEC”) on November 13, 2024. These documents can also be accessed on ARS Pharmaceuticals’ website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab.

The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

ARS Investor Contact:

Justin Chakma
ARS Pharmaceuticals
[email protected]

ARS Media Contact:

Christy Curran
Sam Brown Inc.
615.414.8668
[email protected]

References:

1. Hogue SL, Muniz R, Herrem C, Silvia S, White MV. Barriers to the Administration of Epinephrine in Schools. J Sch Health. 2018 May;88(5):396-404. doi: 10.1111/josh.12620. PMID: 29609214.
2. Kao, L. M., Wang, J., Kagan, O., Russell, A., Mustafa, S. S., Houdek, D., Smith, B., & Gupta, R. (2018). School nurse perspectives on school policies for food allergy and anaphylaxis. Annals of Allergy, Asthma and Immunology, 120(3), 304-309. https://doi.org/10.1016/j.anai.2017.12.019

RISHON LE ZION, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), a global integrator of supply chain technologies, today announced its initial financial outlook for 2025. The Company expects revenue of at least $44 million, and net income of at least $2.4 million, based on its current operating plans.

The Company’s initial 2025 outlook does not include the benefit of potential strategic acquisitions that may add further scale, operating synergies or net income accretion to its operating model.

“Our 2025 plan anticipates year-over-year revenue growth of at least 10 percent from our 2024 guidance of approximately $40 million, plus corresponding increased profitability at the net income line. These results will be driven by new customer contract awards from our robust sales pipeline, increased defense spending in key markets and potential growth in RFID division activity. We expect to pair this revenue growth with steady execution across our business verticals and continued operating cost efficiency to further increase our net income performance,” said Eyal Cohen, Chief Executive Officer of BOS.

“We also continue to carefully evaluate potential tuck-in opportunities for 2025 that may add complementary capabilities that our customers are seeking from BOS and enhance the scale of our existing business lines,” said Cohen.

About BOS Better Online Solutions Ltd.

BOS integrates cutting-edge technologies to streamline and enhance supply chain operations across three specialized divisions:

• Intelligent Robotics Division: Automates industrial and logistics inventory processes through advanced robotics technologies, improving efficiency and precision.
• RFID Division: Optimizes inventory management with state-of-the-art solutions for marking and tracking, ensuring real-time visibility and control.
• Supply Chain Division: Integrates franchised components directly into customer products, meeting their evolving needs for developing cutting-edge products.

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the continued availability of financing for working capital purposes and to refinance outstanding indebtedness; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission.

In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, in response to extensive rocket attacks by Hezbollah on Israel, Israel has launched a military campaign in Lebanon. The clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflicts or their long term effects on our business, operations and financial conditions. The ongoing conflicts are rapidly evolving and developing, and could disrupt our business and operations, interrupt our sources and availability of supply and hamper our ability to raise additional funds or sell our securities, among others.

BOS undertakes no obligation to publicly update or revise any forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

For additional information, contact:

Matt Kreps, Managing Director
Darrow Associates
+1-214-597-8200
[email protected]

Eyal Cohen, CEO
+972-542525925
[email protected]

FREMONT, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that it will host a conference call and webcast on Tuesday, Feb. 4, 2025 at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results for the period ended Dec. 31, 2024. The live webcast can be accessed on the Enphase Energy Investor Relations website at investor.enphase.com, and a recorded version of the call will also be available there approximately one hour after the call.

What:	Enphase Energy’s Fourth Quarter and Full Year 2024 Financial Results Earnings Conference Call and Webcast
Date:	Tuesday, Feb. 4, 2025
Time:	4:30 p.m. Eastern Time
Live Call:	833.634.5018
International:	+1.412.902.4214
Replay:	United States: 877.344.7529
	International: +1.412.317.0088
	Canada: 855.669.9658
	Replay access code: 3831590

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power—and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped approximately 78.0 million microinverters, and over 4.5 million Enphase-based systems have been deployed in more than 160 countries. For more information, visit https://enphase.com/.

©2025 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Contact:

Zach Freedman
Enphase Energy, Inc.
Investor Relations
[email protected]

This press release was published by a CLEAR® Verified individual.

SAN JOSE, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that C3ntro Telecom (C3ntro), Mexico’s leading provider in AI-enabled fiber networks and data center connectivity solutions in Mexico and the U.S., successfully deployed Infinera’s GX Series-based ICE6 800G solution and GX Open Line System (GX OLS) to upgrade and connect its long-haul network between Mexico City and Queretaro and interconnect all data centers across both cities with a groundbreaking capacity of 1.6 Tb/s (2x800G) optical redundant transmission. The upgraded network will offer new and enhanced data center services in key markets in Mexico to meet the increasing demands of its customers.

C3ntro Telecom, a licensed Mexican operator, delivers a carrier-grade fiber network across 3,000 km of Mexico’s top cities, offering dark fiber and wavelength services for seamless, low-latency data center interconnectivity. Purpose-built for hyperscalers, carriers, and cloud service providers, it supports existing and upcoming facilities with redundant infrastructure.

This deployment enables C3ntro Telecom to upgrade its network with Infinera’s GX Series solution. C3ntro has expanded fiber capacity and enhanced performance with 100G and 400G wavelengths to support high-bandwidth applications between all data centers in Mexico and Queretaro. This robust, future-proof connectivity addresses growing demands driven by AI-powered applications and cloud-based solutions, enabling data center operators to offer their customers high-capacity, cost-effective services with reliability and superior performance.

“With over 30 years of experience in delivering integrated cutting-edge solutions, we have become a trusted network operator in the region. We selected Infinera’s GX Series solution for this critical network upgrade for its reliable open optical and high performance – enabling us to interconnect data centers with the capabilities and services that our customers demand. Infinera’s team delivered on a short deployment schedule and upgraded our network in record time without compromising quality,” said Simon Masri, C3ntro Telecom CEO.

“With Infinera’s proven track record of delivering innovative solutions, we are excited to partner with C3ntro to deploy our GX Series solution across Mexico, helping C3ntro offer expanded and enhanced services to their customers,” said Nick Walden, Senior Vice President, Worldwide Sales at Infinera. “Infinera’s solutions provide network operators like C3ntro with scalable, high-performance optical solutions that can be quickly deployed without interruption of service to allow companies to upgrade their networks to meet rapidly increasing customer demands.”

Contacts:

Infinera Media:

Anna Vue
Tel. +1 (916) 595-8157
[email protected]

Infinera Investors:

Amitabh Passi, Head of Investor Relations
Tel. +1 (669) 295-1489
[email protected]

C3ntro Data & Infrastructure Sales:

Carlos Mendoza
Tel. +52 55 6088 0368
[email protected] 

C3ntro Sales:

Tel. +52 55 5147 80 40
[email protected]

About C3ntro

C3ntro Telecom operates a state-of-the-art carrier-grade fiber network across Mexico’s major cities, offering dark fiber and wavelength services for low-latency, high-performance data center interconnectivity. Designed for hyperscalers, carriers, and cloud service providers, our network features reliable, redundant infrastructure to support current and future needs. With over 30 years of experience, we also provide voice, SMS, virtual numbers, and traffic management services, making us a trusted partner for carriers, CPaaS providers, and enterprises. For more information, visit www.c3ntro.com or contact [email protected].

Follow us on LinkedIn   Facebook   Instagram   Twitter (X)

About Infinera

Infinera is a global supplier of innovative open optical networking solutions and advanced optical semiconductors that enable carriers, cloud operators, governments, and enterprises to scale network bandwidth, accelerate service innovation, and automate network operations. Infinera solutions deliver industry-leading economics and performance in long-haul, submarine, data center interconnect, and metro transport applications. To learn more about Infinera, visit www.infinera.com, follow us on Twitter and LinkedIn, and subscribe for updates.

Infinera and the Infinera logo are registered trademarks of Infinera Corporation.

This press release contains forward-looking statements, including but not limited to the operational, performance and financial benefits of Infinera’s GX Series solution. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera’s business, is contained in the risk factors section and other sections of Infinera’s Quarterly Report on Form 10-Q for the Fiscal Quarter ended September 28, 2024 as filed with the SEC on November 5, 2024, as well as any subsequent reports filed with or furnished to the SEC. These reports are available on Infinera’s website at www.infinera.com and the SEC’s website at www.sec.gov. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies and can be identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would” or similar words. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

ANDOVER, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that the Company will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 12, 2025.

A conference call with management will be held on Thursday, February 13, 2025 at 8:30 a.m. (Eastern Time). A live and archived webcast of the call can be accessed on the company’s website at https://investor.mks.com/, or by registering as a Participant by clicking here. We encourage participants to register at least 15 minutes before the start of the call.

About MKS Instruments

MKS Instruments enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

MKS Investor Relations Contact

:

Paretosh Misra, VP, Investor Relations
Telephone: (978) 284-4705
Email: [email protected]

TUSTIN, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) recommend that Avid stockholders vote “FOR” the Company’s pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”).

Nick Green, president and CEO of Avid Bioservices, said, “We are pleased that ISS and Glass Lewis recognize the premium value of the GHO and Ampersand transaction for Avid stockholders, as well as the process run by our Board of Directors to ensure we are maximizing value. We encourage our stockholders to vote FOR our transaction with GHO and Ampersand today.”

In making its recommendation, ISS stated in its January 17, 2025, report:*

• “The sales process was sufficiently thorough, shareholders are receiving a premium, the implied valuation supports the premium being offered, and the cash consideration provides liquidity and certainty of value for shareholders.”

VOTE TODAY The Avid Board of Directors Unanimously Recommends that Avid Stockholders Vote “FOR” the proposed transaction with GHO and Ampersand. Vote TODAY online, by telephone or by signing and returning the enclosed proxy card. If you have questions or need assistance voting your shares, please contact: MacKenzie Partners, Inc.  7 Penn Plaza New York, New York 10001 U.S. & Canada Toll-Free: 1-800-322-2885 Elsewhere Call Collect: +1-212-929-5500 Or Email: [email protected]

* Permission to use quotations was neither sought nor obtained.

Advisors

Moelis & Company LLC is serving as exclusive financial advisor to Avid, and Cooley LLP is serving as legal counsel to Avid.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ: CDMO) is a dedicated CDMO focused on development and CGMP manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

ADDITIONAL INFORMATION AND WHERE TO FIND IT

The Company has filed a proxy statement with the U.S. Securities and Exchange Commission (“SEC”) with respect to a special meeting of stockholders to be held in connection with the proposed transaction. Promptly after filing the definitive proxy statement with the SEC, the Company mailed the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the proposed transaction. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the preliminary and definitive versions of the proxy statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the proposed transaction at the SEC’s website (http://www.sec.gov). Copies of the preliminary and definitive versions of the proxy statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the proposed transaction will also be available, free of charge, at the Company’s investor relations website (https://ir.avidbio.com/sec-filings). The information provided on, or accessible through, our website is not part of this press release, and therefore is not incorporated herein by reference.

PARTICIPANTS IN THE SOLICITATION

The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding the Company’s directors and executive officers is available in the Company’s definitive proxy statement for the January 30, 2025 special meeting of stockholders, which was filed with the SEC on December 18, 2024 (the “Special Meeting Proxy Statement”). Please refer to the sections captioned “Security Ownership of Certain Beneficial Owners, Directors and Management” and “Interests of Avid’s Directors and Executive Officers in the Merger” in the Special Meeting Proxy Statement. To the extent holdings of such participants in the Company’s securities have changed since the amounts described in the Special Meeting Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC: Form 4, filed by Nicholas Stewart Green on January 2, 2025, Form 4, filed by Daniel R. Hart on January 2, 2025, Form 4, filed by Richard A. Richieri on January 2, 2025, and Form 4, filed by Richard A. Richieri on January 13, 2025. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Special Meeting Proxy Statement and other relevant materials filed with the SEC in connection with the proposed transaction. Free copies of the Special Meeting Proxy Statement and such other materials may be obtained as described in the preceding paragraph.

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company’s expectations, intentions or strategies regarding the future, or the completion or effects of the proposed sale of Avid to GHO and Ampersand. In some cases, these statements include words like: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could delay the consummation of the proposed transaction or cause the parties to abandon the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with the proposed transaction; the possibility that the Company’s stockholders may not approve the proposed transaction; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock; the risk of any unexpected costs or expenses resulting from the proposed transaction; the risk of any litigation relating to the proposed transaction; and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2024 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at http://www.sec.gov.

The forward-looking statements included in this information statement are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contacts:

Avid Bioservices

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons
Vida Strategic Partners
415-675-7402
[email protected]

Bob Marese / John Bryan (For Voting Inquiries)
MacKenzie Partners, Inc.
1-800-322-2885
[email protected]

Aaron Palash / Allison Sobel (Media)
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

COOTAMUNDRA, New South Wales, Jan. 21, 2025 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited, a Cayman Islands exempted company (the “Company”) (NASDAQ: COOT) today announced a partnership with Shanghai Maiwei Trading Co., Ltd for the sales, marketing, and distribution of its GEO brand in China.

The GEO brand features a premium range of Australian cold-pressed, non-GMO canola oil and olive oil. Shanghai Maiwei will oversee all GEO branding activities in China, supported by teams in Shanghai, Shenzhen, and Hebei. The Shenzhen team, with extensive e-commerce expertise, will lead online promotions and offline collaborations with supermarkets and private channels. Warehouses in Shanghai and Hebei will ensure efficient nationwide distribution. The “chemical-free” canola and olive oil market in China is steadily growing due to increasing consumer awareness about healthier food options. Moreover, the growing middle class in China with more purchasing power to opt for premium oils has also been driving demand.

“This partnership marks a significant step in bringing high-quality Australian oils to Chinese consumers,” said Gary Seaton, Chief Executive Officer. “The strong potential for our GEO brand in China, combined with our partner’s established market presence and deep regional expertise, creates a solid foundation for sustainable growth.”

About Australian Oilseeds Investments Pty Ltd. Australian Oilseeds Investments Pty Ltd. is an Australian proprietary company that, directly and indirectly through its subsidiaries, is focused on the manufacture and sale of sustainable oilseeds (e.g., seeds grown primarily for the production of edible oils) and is committed to working with all suppliers in the food supply chain to eliminate chemicals from the production and manufacturing systems to supply quality products to customers globally. The Company engages in the business of processing, manufacture and sale of non-GMO oilseeds and organic and non-organic food-grade oils, for the rapidly growing oilseeds market, through sourcing materials from suppliers focused on reducing the use of chemicals in consumables in order to supply healthier food ingredients, vegetable oils, proteins and other products to customers globally. Over the past 20 years, the Company’s cold pressing oil plant has grown to become the largest in Australia, pressing strictly GMO-free conventional and organic oilseeds.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our financial outlook, business strategy and plans, market trends and market size, opportunities and positioning. These forward-looking statements are based on current expectations, estimates, forecasts and projections. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms and similar expressions are intended to identify these forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. For example, global economic conditions could in the future reduce demand for our products; we could in the future experience cybersecurity incidents; we may be unable to manage or sustain the level of growth that our business has experienced in prior periods; our financial resources may not be sufficient to maintain or improve our competitive position; we may be unable to attract new customers, or retain or sell additional products to existing customers; we may experience challenges successfully expanding our marketing and sales capabilities, including further specializing our sales force; customer growth could decelerate in the future; we may not achieve expected synergies and efficiencies of operations from recent acquisitions or business combinations, and we may not be able to pay off our convertible notes when due. Further information on potential factors that could affect our financial results is included in our most recent Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release represent our views only as of the date of this press release and we assume no obligation and do not intend to update these forward-looking statements.

Contact

Australian Oilseeds Holdings Limited
126-142 Cowcumbla Street
Cootamundra New South Wales 2590
Attn: Bob Wu, CFO
Email: [email protected] 

Investor Relations Contact

Reed Anderson
(646) 277-1260
[email protected] 

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath^® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access to critical therapies for the estimated 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs.

This engagement leverages WSI PBG’s proven expertise in navigating the VA and other federal facilities, including access, procurement processes, and regulations, to meet the unique needs of federal healthcare systems. With a shared commitment to improving health outcomes, CorMedix and WSI PBG will work together to provide patients at the VA and other federal facilities with increased access to DefenCath.

Joe Todisco, CorMedix CEO, commented, “We are excited to announce our collaboration with such an established and successful government sales organization fully dedicated to the VA and federal facilities. Their deep understanding of the federal healthcare landscape will help us increase access to DefenCath and ensure equitable care for our country’s veterans and others who benefit from the federal healthcare system.”

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576

BURLINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global industry leader in AI for transportation, will announce its first quarter financial results for the quarter ended December 31, 2024, on Thursday, February 6, 2025, at 4:05pm Eastern Time / 1:05pm Pacific Time.

The company will host a live conference call and webcast, with supplementary slides, to discuss the results on the same day at 5:00pm Eastern Time / 2:00pm Pacific Time. Interested investors and analysts are invited to join the audio conference call by registering here.

Webcast access will be available in the Investor section of the company’s website, www.cerence.ai.

To learn more about Cerence AI, visit www.cerence.ai, and follow the company on LinkedIn.

About Cerence Inc.

Cerence Inc. (NASDAQ: CRNC) is a global industry leader in creating intuitive, seamless, AI-powered experiences across automotive and transportation. Leveraging decades of innovation and expertise in voice, generative AI, and large language models, Cerence powers integrated experiences that create safer, more connected, and more enjoyable journeys for drivers and passengers alike. With more than 500 million cars shipped with Cerence technology, the company partners with leading automakers, transportation OEMs, and technology companies to advance the next generation of user experiences. Cerence is headquartered in Burlington, Massachusetts, with operations globally and a worldwide team dedicated to pushing the boundaries of AI innovation. For more information, visit www.cerence.ai.

Contact Information

Investor Relations | Email: [email protected]

Kate Hickman | Tel: 339-215-4583 | Email: [email protected]

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — Fiverr (NYSE: FVRR), the company changing how the world works together, today announced the continued expansion of its business accelerator program with its largest cohort of 15 founders into its fourth annual business accelerator, The Future Collective. Founders in the six-month accelerator program, which supports underrepresented entrepreneurs, will receive a combination of resources designed to support business growth, including cash and Fiverr credits, access to workshops, and one-on-one coaching.

Spanning across industries, this year’s cohort represents businesses ranging from lifestyle brands, including fashion and accessories, health and wellness, and food and beverage, to business services like web design, digital experiences and construction. From veteran-owned businesses to first-generation immigrant entrepreneurs, this year’s cohort represents a diverse range of backgrounds from 11 states nationwide.

“Small businesses are the backbone of the economy and we’re continually amazed and inspired by the work of the founders of The Future Collective,” said Micha Kaufman, Founder and CEO of Fiverr. “It is a privilege to be a part of their journeys, and we’re thrilled to expand the program to support even more founders and businesses.”

The fifteen businesses and founders that comprise Fiverr’s 2025 Future Collective cohort are:

• Abeille Creations (Miami, FL): Founded by Melissa Mitchell, Abeille Creations is a fashion brand and design house that specializes in creating apparel, home decor, clothing, and accessories with a focus on art.
• Bri’s Dance (Merrillville, IN): Bri’s Dance Place, founded by Brianna Hairlson, is a multi-generational dance studio focusing on age-appropriate choreography, costumes, and music.
• Digital Flagship (Jersey City, NJ): Digital Flagship is a web design & development studio founded by AJ Camara that specializes in building engaging online experiences for direct-to-consumer e-commerce brands and tech startups.
• Goodies Frozen (Alexandria, VA): Founded by Brandon Byrd, Goodies Frozen offers Wisconsin-style Frozen Custard and nostalgic treats inspired by a classic 1950s soda fountain.
• Inclusive Communication Services (New York, NY): Inclusive Communications Services is an accessibility solutions provider founded by Shelby Edwards that offers spoken and sign language interpretation, translations, captions, and media.
• Junobie (West Lafayette, IN): Founder and mom Nikeytha Ramsey is the creator of Junobie, the world’s first reusable breast milk bag and storage solutions.
• Just Elope LLC (Dallas, TX): Just Elope, founded by Jennifer Allen, plans luxurious micro weddings in 24 hours while offering expert guidance on navigating married life.
• Luxe Gather (Coral Springs, FL): Luxe Gather, founded by Tiffany Morris, is a mobile events company specializing in unique spa and gaming party experiences for kids.
• Main Attraction (Charlotte, NC): Founded by Arion Herbert, Main Attraction is a community-driven sports organization that promotes a healthy social environment through organized kickball games and tournaments.
• Mixed Up (Los Angeles, CA): Mixed Up Clothing is a veteran-owned children’s fashion brand founded by Sonia Smith Kang. It celebrates and promotes cultural awareness through vibrant, globally inspired designs that empower kids to embrace their heritage.
• Mom Juice (Denver, CO): KT Winery, best known for its brand Mom Juice founded by Kristin Taylor, offers low-sugar, gluten-free and vegetarian wines made with nine ingredients or less.
• Supermixers (Orlando, FL): Supermixers is a global construction equipment supplier founded by Daniel Bracho that delivers top-quality concrete solutions to over 15 countries.
• Theramotive (New York, NY): TheraMotive, founded by Dr. Lola Omishore, builds innovative portable clinics to serve all of New York City, filling the void in healthcare access for all patients.
• TJL Collection (Memphis, TN): Created by Tiffany Jones-Lewis, TJL Collection is a women’s fashion brand focused on pants with longer inseams for individuals who are 5’9 and taller.
• Whims Delight (Austin, TX): Whims is a new chocolate brand created by husband-and-wife duo Leanne Viola and Jesse Barruch, specializing in low-sugar, gluten-free, and dairy-free chocolate treats.

Making a valuable impact on the founders and businesses in the program, the Future Collective’s 2024 cohort reported that 13 business opportunities were generated from the program, 89 meaningful connections were made, and their average projected revenue increased by 43%. Highlights include BrickRose Exchange seeing its revenue increase by 20% since joining The Future Collective, while Talent Poole shared that it tripled the value of one of its contracts by redefining its services and packages — a move directly attributed to the coaching she received.

The Future Collective is an accelerator program by Fiverr for early-stage U.S. and Canada-based underrepresented entrepreneurs at pivotal moments in their business. Awardees receive $8,000 in cash and $4,000 in Fiverr credits, and six months of education and coaching overseen by Fiverr and 1863 Ventures, a DC-based organization working to accelerate founders historically underestimated from high potential to high growth. Launched in 2021, The Future Collective has since expanded from supporting five entrepreneurs to supporting 15 founders from all underrepresented communities.

About Fiverr

Fiverr’s mission is to change how the world works together. We exist to democratize access to talent and to provide talent with access to opportunities so anyone can grow their business, brand, or dreams. From small businesses to Fortune 500, around 3.8 million customers worldwide worked with freelance talent on Fiverr in the past year, ensuring their workforces remain flexible, adaptive, and agile. With Fiverr Business Solutions, large companies can find the right talent and tools tailored to their needs to help them thrive and grow. On Fiverr, you can find over 700 skill categories, ranging from AI to programming and 3D design, digital marketing to content creation, and from video animation to architecture.

Don’t get left behind – come be a part of the future of work by visiting fiverr.com, reading our blog, and following us on Instagram,X, and Facebook.

Press Contacts:

Jenny Chang
Tommy Lee
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/23da85b2-8b29-4b45-805a-e3c813bd6b35